Form 4: Rapport Therapeutics CEO Sells Over 76K Shares in Planned Sale

Rapport Therapeutics, Inc. CEO Abraham Ceesay reported the sale of 76,420 shares of common stock for approximately $2.01 million through pre-arranged 10b5-1 trading plans.

Summary

• Abraham Ceesay, Chief Executive Officer and Director of Rapport Therapeutics, Inc. (RAPP), reported transactions involving the sale of common stock.
• A total of 76,420 shares were sold on September 17, 2025, through multiple transactions.
• The sales were executed pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024.
• 40,835 shares were sold directly by Mr. Ceesay at weighted average prices ranging from $26.299 to $26.8745 per share.
• 35,585 shares were sold indirectly through The Dorothy Ceesay Irrevocable Trust at weighted average prices ranging from $26.3019 to $27.0429 per share.
• The total proceeds from these sales amount to approximately $2,010,000.
• Following these transactions, Mr. Ceesay directly beneficially owns 585,412 shares of common stock.
• Indirect beneficial ownership includes 46,144 shares held by The Dorothy Ceesay Irrevocable Trust and 81,729 shares held by The Ceesay Family Irrevocable Trust.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While a CEO selling shares can sometimes be viewed negatively, the fact that these sales were conducted under a pre-arranged 10b5-1 plan mitigates concerns about opportunistic selling, making it a more routine financial management event.

Positives

• The sales were conducted under pre-arranged Rule 10b5-1 trading plans, indicating a structured and planned approach to insider stock transactions rather than an opportunistic sale.

Negatives

• The Chief Executive Officer and Director selling a significant number of shares (76,420) could be perceived by some investors as a reduction in insider conviction or a signal of limited upside potential.
• The total value of shares sold, approximately $2.01 million, represents a notable divestment by a key executive.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing reports a routine insider transaction and does not provide specific insights into broader industry trends or competitive landscape for Rapport Therapeutics, Inc. within the biotechnology sector.

Related Party Transactions

• Sales of 35,585 shares were made indirectly through The Dorothy Ceesay Irrevocable Trust, for which the Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders may interpret the CEO's sale of shares as a signal, potentially influencing their perception of the company's near-term prospects, although the 10b5-1 plan suggests a pre-planned financial move rather than a reaction to new information.

Key Dates

Recommendation

The filing reports a significant insider sale by the CEO, which could be a minor negative signal. However, the sales were conducted under a pre-arranged 10b5-1 plan, suggesting a planned diversification or liquidity event rather than a reaction to adverse company-specific news. This makes the transaction less alarming than an ad-hoc sale. Without additional financial or operational context, a 'hold' recommendation is appropriate, acknowledging the insider sale while recognizing its pre-planned nature.

Keywords

Rapport Therapeutics, RAPP, SEC Form 4, Insider Trading, Stock Sale, CEO, Abraham Ceesay, 10b5-1 Plan, Biotechnology, Pharmaceuticals